Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
7.88
-0.25 (-3.08%)
At close: Mar 9, 2026, 4:00 PM EDT
7.75
-0.13 (-1.65%)
After-hours: Mar 9, 2026, 5:06 PM EDT
Lipocine Revenue
Lipocine had revenue of $114.57K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $4.32M, down -45.44% year-over-year. In the year 2024, Lipocine had annual revenue of $11.20M, down -492.80%.
Revenue (ttm)
$4.32M
Revenue Growth
-45.44%
P/S Ratio
10.35
Revenue / Employee
$270,168
Employees
16
Market Cap
43.75M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLPCN News
- 19 days ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 6 weeks ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PRNewsWire
- 3 months ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 4 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 4 months ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire
- 5 months ago - Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PRNewsWire